Equity Overview
Price & Market Data
Price: $0.15
Daily Change: +$0.0145 / 9.67%
Range: $0.13 - $0.189
Market Cap: $7,544,040
Volume: 102,661
Performance Metrics
1 Week: -5.77%
1 Month: -21.07%
3 Months: -75.59%
6 Months: -67.38%
1 Year: -92.44%
YTD: -81.44%
Company Details
Employees: 63
Sector: Finance
Industry: Financial conglomerates
Country: United States
Details
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.